Israeli generics manufacturer Teva Pharmaceuticals intends to divest its active pharmaceutical ingredient (API) business, Teva API (TAPI). A standalone business unit of Teva, TAPI supplies APIs to over 1,000 customers worldwide and has approximately 4,300 employees worldwide.
Arkema has increased its global manufacturing capacity for Pebax elastomers by 40% at its Serquigny plant in France, which is utilized in particular in the sports and consumer goods markets.
Austrian oil, gas and chemicals group OMV has signed an agreement to divest its 50% stake in Malaysia’s natural gas producer SapuraOMV Upstream to TotalEnergies for $903 million, including the transfer of a $350 million loan granted by OMV to SapuraOMV.
Veranova has appointed Chris Holmes as the company’s first vice president, Global Engineering. He will lead Veranova’s global engineering team in the planning, design, and execution of the company’s capital investment initiatives and lead strategic capital projects.
IMCD has appointed Natasha De Lange as managing director for South Africa, effective Feb. 1, 2024. She will be replacing Ryan Harrison, who will become managing director of Australia and New Zealand.
Swiss contract development and manufacturing organization (CDMO) Lonza will collaborate with Oxford Nanopore Technologies, a UK-based company delivering a new generation of nanopore-based molecular sensing technology. The collaboration aims to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA (mRNA).
Last week, AbbVie broke ground on a new Singapore manufacturing facility located in Singapore's Tuas Biomedical Park. The company will invest $223 million in the site which will add 24,000 l of biologics drug-substance capacity to AbbVie's global manufacturing network and support current products as well as emerging immunology and oncology compounds within its pipeline.
Hungary-headquartered specialty pharmaceutical company Gedeon Richter becomes a strategic investor of German biosimilars company Formycon via cash capital increase of 9.08% of Formycon’s share capital, which corresponds to €82.84 million.
German chemicals, pharmaceuticals and life sciences group Merck has opened a digital hub in Singapore, the first outside of the US and Europe for its digital business.
Olon Group is building a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite at its Olon USA site in Concord, Ohio. This expands the company's capabilities for handling HPAPI, with investments totaling around €40 million ($43 million) in recent years.
Dutch ingredients producer Corbion has agreed to divest its emulsifier business to US private equity firm Kingswood Capital Management for $362 million. The transaction, which is expected to close in the second quarter of this year, is contingent upon the satisfaction of certain conditions, including regulatory approvals.
Active pharmaceutical ingredients manufacturer EuroAPI has started a collaboration with Basel, Switzerland-headquartered SpiroChem, a contract research organization (CRO) which specializes in early chemical process R&D (route scouting).
In a move to meet the rising demand from the photovoltaic industry, Solvay is expanding the is hydrogen peroxide capacity of its Shandong Huatai Interox Chemical site in China, a joint venture (JV) with Huatai Chemical.
SGD Pharma announced the opening of a new siliconization operation at its Saint-Quentin Lamotte (SQLM) plant. The company enhances its range of in-house services by internalizing its glass siliconization offer, ensuring increased responsiveness, security of supply and improved flexibility of vial sizes.
Leading Indian carbon black player Birla Carbon announced to establish two new carbon black manufacturing sites in Naidupet, Andhra Pradesh, India, and Rayong, Thailand.
The Kenyan start-up Molepse BioResources has developed two products, one for small-scale and one for large-scale grain farmers, to protect their harvest from weevil attacks.
Syensqo Ventures, the group’s venture capital fund, participated in the €1.9 million ($2.1 million) financing round for Bioeutectics, alongside Fen Ventures, Atento Capital, and SOSV (IndieBio).
Sanofi agreed to acquire biopharmaceutical company Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx for approximately $1.7 billion and will also retain an 8% equity stake in New Inhibrx. Sanofi said that it expects to finance the transaction with available cash resources.
BP has appointed Murray Auchincloss as its permanent CEO, effective immediately. He has been interim CEO since September 2023 after the sudden resignation of his predecessor Bernard Looney.
German drugmaker Boehringer Ingelheim is investing €120 million in an upgrade and expansion of its facility in Koropi, Greece, that will increase the company's capacity to produce existing and new medicines. Main disease areas, Boehringer said, include cardio-renal-metabolic (CRM) diseases, mental health, and pulmonary fibrosis.
LyondellBasell (LYB) has agreed to acquire a 35% stake in Saudi Arabia-based National Petrochemical Industrial Company (Natpet) from Alujain for approximately $500 million. Closing of the transaction is subject to regulatory and other customary closing conditions.
Italian specialty additives manufacturer Italmatch Chemicals agreed to purchase the majority of shares of Alcolina, a Brazilian chemicals company specialized in water treatment for bioethanol, sugar production and industrial applications. Financial details of the transaction were not disclosed.
Following its long-term goal of extracting itself from a challenging operating environment in the Niger Delta, Shell agreed to sell its Nigerian onshore subsidiary Shell Petroleum Development Company of Nigeria (SPDC) to Renaissance, a consortium of five companies comprising four exploration and production companies based in Nigeria and an international energy group, for $1.3 billion.
International Flavors & Fragrances (IFF) has appointed J. Erik Fyrwald as next CEO and member of the company’s board of directors, effective Feb. 6, 2024. He will succeed Frank Clyburn, who will remain with the IFF until the end of March and will continue to work in an advisory capacity until December 2024.
China-headquartered contract research, development and manufacturing organization (CRDMO) WuXi Biologics plans to increase the manufacturing capacity of its US facility in Worcester, Massachusetts to 36,000 l, 12,000 l more than the originally planned 24,000 l.
Solenis to invest €176 million ($193 million) in City of Suffolk facility expansion. The company will build a new 7430-square-meter (80,000-square-foot) production facility, packaging facility, and tank farm. This new facility will be used to grow the existing polymer product line and add additional capacity of this critical monomer to the existing supplier.
French chemical producer Arkema announced that it will become a shareholder of Tiamat, a start-up that designs, develops, industrializes and markets sodium-ion batteries, a new lithium-free technology. Tiamat was spun off from the Centre National de la Recherche Scientifique (CNRS) in 2017.
Nouryon has completed a production capacity expansion of nearly 50% for its Levasil colloidal silica products at its US manufacturing facility in Green Bay, Wisconsin.
Global specialty chemicals group Altana has announced to acquire Silberline, a US company that specializes in developing and manufacturing aluminum effect pigments utilized in various applications, ranging from automotive coatings and printing inks to plastics, protective coatings, and packaged consumer goods.
Isomorphic Labs announced strategic collaborations with leading pharmaceutical companies, Eli Lilly and Company and Novartis. These partnerships have the potential to be worth nearly €2.75 billion ($3 billion) to Isomorphic Labs, excluding any royalties that may result from future drug sales. Both collaborations are multi-target, focused on small molecules, and include a combination of upfront and milestone payments.
GSK has agreed to acquire biotech Aiolos Bio for a $1 billion upfront payment and up to $400 million for the achievement of certain milestones. Founded just last year, Aiolos is a San Francisco, USA and London, UK-based biopharmaceutical company that develops treatments for respiratory diseases.
Johnson & Johnson has entered into a definitive agreement to acquire Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). The all-cash merger transaction for a total equity value of approximately €1.8 billion ($2.0 billion), or €1.75 billion ($1.9 billion) net of estimated cash acquired.
US Merck & Co., known as MSD outside of North America, intends to buy cancer drug developer Harpoon Therapeutics for $23.00 per share in cash for an approximate equity value of $680 million.
IMCD has appointed Fenna van Zanten, IMCD Group Director, Mergers & Acquisitions (M&A), and Andreas Igerl, President, IMCD APAC, as new members to its executive committee, effective Jan. 1, 2024.
CordenPharma and pHLIP have announced their strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and genetic therapeutics.
